ShangPharma appoints pharmaceutical executive Mitchell Reff as chief biologics officer

China-based ShangPharma has named Mitchell Reff as the company’s chief biologics officer. The company said the appointment strengthens the technical capabilities of ChemPartner's Biologics Division and offers pharmaceutical and biotechnology companies from around the world strategic and technical expertise to discover and manufacture novel first-in-class and best-in-class biologic clinical development candidates to advance into company pipelines.

Dr Reff brings more than 30 years of research and development experience in the biopharmaceutical industry. His career includes eight years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering before he joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr Reff had a distinguished 21 year career at Idec, and later at US biotech firm Biogen Idec (Nasdaq: BIIB). He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered six novel oncology drugs into clinical trials in five years.

Key achievements